Psilocybin Therapy Pilot for Anorexia Nervosa: Promising Results

Psilocybin Therapy Shows Promise in Treating Anorexia Nervosa

A recent pilot study has demonstrated that psilocybin therapy may offer a new avenue for treating anorexia nervosa, a severe eating disorder with limited effective treatments. Conducted with 21 adult females, the study explored the safety and potential efficacy of psilocybin, administered in three dosing sessions over six weeks. The results suggest significant improvements in eating disorder symptoms and motivation to change, although outcomes varied among participants.

Mechanism and Context of the Study

This study utilized oral psilocybin (COMP360) in a structured therapeutic setting, alongside traditional talk therapy. Participants received doses of 1 mg, 25 mg, and 25 mg, with primary outcomes measured using the Eating Disorder Examination Interview (EDE) and Readiness and Motivation Questionnaire (RMQ). The study observed significant improvements in EDE scores at the 6-month mark and RMQ scores at 12 months, indicating enhanced readiness to change.

Policy and Research Implications

The findings from this pilot study underscore the need for larger, more rigorous trials to confirm psilocybin's efficacy and safety in treating anorexia nervosa. If validated, psilocybin therapy could expand beyond psychiatric conditions to include severe eating disorders, potentially influencing treatment guidelines and healthcare policies. This study also highlights the importance of integrating psychedelic therapies into existing treatment frameworks, ensuring comprehensive care for patients.

Risks and Unknowns

While the study reported that psilocybin was generally well tolerated, with common adverse events including headaches and nausea, two serious adverse events (suicide attempts) occurred within the 6–12-month follow-up period. This underscores the necessity of closely monitoring patients and ensuring robust support systems during and after treatment. The variability in outcomes also suggests that individual differences may significantly influence treatment efficacy, warranting further investigation.

Looking Forward

As the field of psychedelic research continues to evolve, this study contributes valuable insights into psilocybin's potential role in treating anorexia nervosa. Future research should focus on optimizing dosing regimens, understanding individual variability, and integrating psilocybin therapy into broader treatment paradigms. As interest in psychedelic therapies grows, stakeholders must balance enthusiasm with caution, prioritizing patient safety and evidence-based practice.